Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (July 2014)
25 slides from Champions Oncology's investor presentation, July 2014
Slide 1: A proprietary platform for personalizing cancer
A proprietary platform for personalizing cancer July 2014
Slide 2: Notice of Forward Looking Statements
Notice of Forward Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking
Slide 3: Mission Statement
Mission Statement Building the world’s largest collection of TumorGrafts and chemo-response data to revolutionize the development and use of cancer drugs.
Slide 4: Company History
Company History The current CEO and President were hired in 2010 to develop the technology and grow the company. They have succeeded in building the company and are preparing to accelerate the growth by scaling the platform. 2007 2010 2014 • Founded by 2 • Current CEO and • Completed hiring of oncol
Slide 5: A Deep and Experienced Senior Management Team
A Deep and Experienced Senior Management Team Dr. David Sidransky – Chairman of the Board • Former Vice Chairman, ImClone Systems • Professor of Oncology, Otolaryngology, Cellular and Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins Joel Ackerman – Chief Executive Officer • 15 y
Slide 6: Every Patient Tumor is Unique
Every Patient Tumor is Unique Genetic and epigenetic heterogeneity across the tumors of cancer patients creates significant challenges in developing efficacious cancer drugs. Accurately predicting which patients will respond to a specific drug remains difficult. 6
Slide 7: Most Patients Get Little or No Benefit From Most Oncology Drugs
Most Patients Get Little or No Benefit From Most Oncology Drugs The personalization of oncology drugs remains elusive despite the recent attempts to leverage genomic sequencing to improve patient response to chemotherapy. Patient Response Rate to Chemotherapy1 50% 25% 10% First Line Second Line Thir
Slide 8: Preclinical models of human cancer, in large part, stink
“Preclinical models of human cancer, in large part, stink1” 83% of the cost spent to bring one drug through the FDA successfully is spent on failed clinical trials. This is the result of an inability to predict in advance the likelihood that patients will respond to new treatments. $1.3 BILLION Clin
Slide 9: The Process of Developing TumorGrafts
The Process of Developing TumorGrafts Champions TumorGrafts maintain the heterogeneity and preserve the microenvironment that supports the tumor growth. Limited number of passes used to preserve human characteristics of tumors. Response Study Champions TumorGraft® 1,200 Patient Tumor 800 Tumor Cells
Slide 10: Case Study: Metastatic Ovarian Cancer Patient
Case Study: Metastatic Ovarian Cancer Patient 1600 1400 1200 Tumor Volume, mm3 1000 TumorGraft 800 response 600 to drug testing 400 200 0 -1 0 2 6 9 13 16 20 23 27 Test Day Case: TumorGraft: TumorGraft™ Results: • 72-year-old female Nine regimens tested • Treatment with the MEK • 3 standard of care
Slide 11: Mouse Avatars as a Tool for Personalization
Mouse Avatars as a Tool for Personalization We are developing a predictive chemo-response platform that can personalize the development and use of oncology drugs. Predictive: • Empirical approach incorporates genetic and TumorGrafts epigenetic drivers • >80% accuracy in predicting patient response P
Slide 12: The Predictive Power of TumorGrafts
The Predictive Power of TumorGrafts A growing body of evidence demonstrates positive predictive value for TumorGrafts above 80%. Peer-reviewed publications: 88% objective response rate (n=17) by patients receiving mouse-directed therapy1 81% correlation (n=16) between results from patient TumorGraft
Slide 13: A Well Annotated Patient Population Perpetuated in Champions TumorBank
A Well Annotated Patient Population Perpetuated in Champions TumorBank Fragments of tumor from TumorGrafts are cryo-preserved and can be regrown in mice. This enables us to test experimental drugs on these TumorGrafts as part of the drug development process to understand the efficacy of new drugs. P
Slide 14: Multiple Sources for Further Validation and Growth
Multiple Sources for Further Validation and Growth New patients enable Champions to build on the existing body of evidence as well as grow the scale of the TumorBank. Commercial Clinical Validation Research Diagnostic Test Studies Collaborations Sources of Patients
Slide 15: Personalized TumorGraft Commercialization: Current Status
Personalized TumorGraft Commercialization: Current Status Commercial Operations Patient Implant Growth1 • Available for most solid tumors with different growth characteristics 300 • Requires fresh tissue sample from 250 surgery or biopsy 200 • Active sales efforts in U.S., U.K., 150 Singapore and Is
Slide 16: Champions Patient Population Used to Simulate Clinical Trials
Champions Patient Population Used to Simulate Clinical Trials Collections of TumorGrafts (a.k.a. patients) are chosen by our pharmaceutical company customers to simulate human clinical trials at a fraction of the cost of human trials.
Slide 17: Clinical Trial Simulation Case Studies
Clinical Trial Simulation Case Studies Champions simulated trials are controlled trials that assist pharmaceutical companies in evaluating the efficacy of experimental compounds. Depending on the design, our trials can also assess comparative efficacy relative to standard of care drugs, determine sy
Slide 18: Commercial Offering to Pharmaceutical Industry
Commercial Offering to Pharmaceutical Industry Historical Revenue Growth 4 Year CAGR: 54% $10,000,000 $8,000,000 $6,000,000 $4,000,000 $2,000,000 $0 F2010 F2011 F2012 F2013 F2014
Slide 19: Total Available Market for Clinical Trial Simulation
Total Available Market for Clinical Trial Simulation Champions’ clinical trial simulation capabilities address a large potential market. Champions will need to expand its platform to include more patient tumors to capture more of the market. $ $12 Billion Oncology Clinical Trials x % 13% Simulation
Slide 20: Scaling Up to Capture the Market
Scaling Up to Capture the Market Champions is exiting the proof of concept stage, having proven the technological, operational and commercial viability of the TumorGraft platform. The company is now focusing on scaling to accelerate revenue growth and capture the available market. Access to Patients
Slide 21: Personalizing Cancer By Predicting Response
Personalizing Cancer By Predicting Response Champions is pursuing opportunities to integrate the patient, clinical trial and information aspects of the TumorGraft platform. Synergies between these offerings will further differentiate Champions and offer new revenue opportunities. Patients Informatio
Slide 22: Fiscal 2014 Financial Results
Fiscal 20141 Financial Results Year Ended Year Ended Year over Year April 30 2014 April 30 2013 Change New Patient Implants 312 155 101% Operating Revenue 2 Translational Oncology 9,286 5,933 57% Core Personalized Oncology 1,825 1,469 25% Non-core Revenue 439 921 - 52% $ 11,550 Total operating reven
Slide 23: Stock Information
Stock Information1 Symbol: CSBR (OTC) Revenue run rate: $11.6 million Shares outstanding – Primary shares: 67 million – Fully diluted: 94 million Stock price: $1.00 1 As of July 24, 2014 23
Slide 24: Company Highlights
Company Highlights A unique approach to a large and growing market Commercial stage company with demonstrated revenue and margin growth Innovative technology and products that target additional market opportunities with strong competitive advantages Experienced management team with incentives aligne
Slide 25: Contact Us: Joel Ackerman, Chief Executive Officer
Contact Us: Joel Ackerman, Chief Executive Officer jackerman@championsoncology.com (201) 808-8401
Champions Oncology — Investor Presentation (July 2014) on 6ix